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diabetes, cardiovascular disease, and hepatic steatosis, which 
collectively represent one of the leading causes of adult 
morbidity and mortality worldwide (1–3). This suggests 
that restoration of functional energy homeostasis is critical 
for therapeutic intervention. Despite efforts to develop 
anti-obesity medications that curtail symptoms of meta-
bolic dysfunction, drugs that have reached the market have 
limited efficacy for obesity (5–8%) and many have been 
withdrawn for negative side effects (3–6). Currently avail-
able therapeutics predominantly work by either reducing 
caloric intake or blocking food absorption (3). Addition-
ally, patients often regain lost weight. The treatment strat-
egy with the most robust and lasting improvements is 
gastric bypass surgery, which has shown up to 25% weight 
loss at 12 years together with a 51% remission rate for type 
2 diabetes (7). Presently, gastric bypass surgery as an inter-
vention for obesity and metabolic syndrome is limited to 
patients with a BMI 35 kg/m2 (8), excluding patients 
with moderate obesity, although these patients often pre-
sent with increased metabolic dysfunction and cardiovascu-
lar risk (9, 10). Therefore, there is urgent need for safe and 
effective medical therapies for obesity and its associated 
complications, including the metabolic syndrome and car-
diovascular disease.
Epidemiological studies show an inverse correlation be-
tween flavonoid (a class of plant-derived polyphenols) con-
sumption and the development of type 2 diabetes, metabolic 
syndrome, and atherosclerosis (11, 12). Previous research 
in our laboratory identified the citrus-derived flavonoids, 
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naringenin and nobiletin, as novel therapeutics for the 
prevention of metabolic syndrome and cardiovascular dis-
ease (13–17). These flavonoids have anti-inflammatory 
properties, promote insulin sensitivity, and inhibit apoB100 
secretion from cultured hepatocytes (16, 18–20). When ex-
tended to a mouse model of obesity, metabolic dysfunc-
tion, and atherogenesis, namely the Ldlr/ mouse fed a 
high-fat cholesterol-containing (HFHC) diet, prevention 
studies revealed that supplementation of the HFHC diet 
with naringenin or nobiletin attenuated weight gain and 
adiposity, enhanced insulin signaling, lowered plasma lip-
ids, and prevented systemic inflammation and hepatic ste-
atosis, resulting in slowed atherosclerosis progression 
(13–17). While these studies highlight potential therapeu-
tic utility of the citrus flavonoids, it would be more clini-
cally relevant to assess the efficacy of these compounds in 
an intervention protocol where obesity, insulin resistance, 
hyperlipidemia, and atherosclerosis have been established 
prior to treatment.
In the present study, we show, in Ldlr/ mice with pre-
established diet-induced obesity, metabolic dysregulation, 
and intermediate-stage atherosclerosis, that intervention 
by the addition of either naringenin or nobiletin to a 
HFHC diet not only prevented continued obesity and dete-
rioration in symptoms of the metabolic syndrome but also 
markedly reduced adipose tissue mass, normalized glucose 
homeostasis, and attenuated both hyperlipidemia and 
hepatic steatosis. Correction of metabolic parameters was 
accompanied by a reduction in circulating blood monocytes. 
Collectively, these metabolic improvements did not resolve 
the size of aortic sinus atherosclerotic lesions, but plaques 
in flavonoid-treated mice were characterized by reduced 




Male Ldlr/ mice on a C57BL/6 background (Jackson Labo-
ratory, Bar Harbor, ME) were housed in pairs in standard cages at 
23°C on a 12 h light and dark cycle. The animals were cared for in 
accordance with the Canadian Guide for the Care and Use of 
Laboratory Animals. All experimental procedures were approved 
by the Animal Care Committee at the University of Western On-
tario (protocol #AUP-2016-057). Mice, 10–12 weeks of age (n = 10), 
were fed, ad libitum, a purified rodent chow diet (14% of calo-
ries from fat, Teklad Rodent Diet 8604; Envigo, Madison, WI) 
for 24 weeks. Another group of mice (10–12 weeks of age, n = 120, 
24 per group) were fed a HFHC diet (42% of calories from fat, 
0.2% cholesterol, Teklad TD09268; Envigo) for 12 weeks (base-
line). A subgroup of these HFHC-fed mice (n = 24) were eutha-
nized at 12 weeks to provide baseline data for analyses that 
required euthanization. The remaining mice were divided among 
four different groups and, for the subsequent 12 weeks, one 
group remained on the same HFHC diet (n = 24), one group re-
mained on the HFHC diet supplemented with 3% naringenin 
(#N5893; Millipore-Sigma) (n = 24), one group remained on the 
HFHC diet supplemented with 0.3% nobiletin (#10236-47-2; R&S 
PharmChem, Hangzhou City, China) (n = 24), and one group was 
switched to the standard rodent chow (n = 24). Food intake and 
body weights were measured weekly. Caloric intake was calculated 
as weight of food eaten (grams) per day multiplied by the caloric 
content of each diet (chow 3.0 kcal/g; HFHC 4.5 kcal/g). We 
previously observed a taste aversion with naringenin and nobile-
tin, which was mitigated by slowly increasing the flavonoid dose 
over the first week of intervention to prevent significant impact on 
food intake (data not shown).
Blood and tissue collection
Mice were fasted for 6 h at the start of the light cycle prior to 
blood taking or euthanization. At the time of euthanization, ani-
mals were anesthetized with ketamine-xylazine [100 g/g ket-
amine hydrochloride (Bioniche Animal Health Canada Inc., 
Belleville, ON, Canada) and 10 g/g xylazine (Bayer Healthcare, 
Animal Health Division, Bayer Inc., Toronto, ON, Canada)]. 
Blood was collected via cardiac puncture in syringes containing 
80 l of 7% Na2-EDTA. Blood was centrifuged at 16,000 g for 
10 min at 4°C to separate the plasma, which was stored at 20°C 
for further use. Tissue dissections were performed via midline 
incision. To dissect the heart for histological analysis, the left 
ventricle was perfused with PBS containing heparin (10 units/ml) 
and the right atrium was cut to drain the perfusate. The heart and 
full-length aorta were dissected together. Aortae were rinsed and 
cleaned using a dissecting microscope to remove any adipose tis-
sue. Aortae were snap-frozen in liquid N2 and stored at 80°C for 
mRNA and lipid measurements. The top half of the heart was 
placed in OCT medium, frozen on dry ice, and stored at 80°C 
for histological analyses. Small pieces of both epididymal and in-
guinal white adipose tissue (eWAT, iWAT) were fixed in 4% para-
formaldehyde and paraffin embedded for histological analyses. 
Liver, eWAT, iWAT, brown adipose tissue (BAT), and quadricep, 
gastrocnemius, and soleus muscles were removed, weighed, and 
snap-frozen in liquid N2 and stored at 80°C.
Metabolic cages
From 1 to 4 weeks prior to completion of the intervention 
period, energy expenditure, respiratory exchange ratio (RER), food 
consumption, and locomotor activity were assessed using the 
Comprehensive Laboratory Animal Monitoring System (CLAMS; 
Columbus Instruments, Columbus, OH). Mice were housed in 
metabolic cages with free access to food and water and acclima-
tized for 48 h. For the subsequent 24 h, every 10 min, data on O2 
consumption (VO2; milliliters per hour) and CO2 production 
(VCO2; milliliters per hour) were collected. The RER was derived 
from the ratio of VCO2 to VO2, and energy expenditure was 
determined as (3.815 + 1.232 × RER) × VO2 and expressed as 
ANCOVA-adjusted energy expenditure in kilocalories per hour. 
ANCOVA adjustments to energy expenditure were made based 
on body weight, which allowed for the determination of differ-
ences in energy expenditure independent of group differences 
in body weight. The ANCOVA analysis performed for this work 
was provided by the National Institute of Diabetes and Digestive 
and Kidney Diseases Mouse Metabolic Phenotyping Centers 
(MMPC; www.mmpc.org) using their Energy Expenditure 
Analysis page (http://www.mmpc.org/shared/regression.aspx). 
Ambulatory activity was measured as infrared beam breaks in the 
X, Y, and Z axis per hour. Accumulated food consumption was 
measured in grams and converted to kilocalories based on diet 
composition.
Micro-computed tomography
Mice were first imaged at 12 weeks (baseline) on diet (n = 8 per 
group) and regularly following intervention (weeks 14, 16, 18, 21, 
and 23), as described previously (13). Whole-body composi-
tion analysis was conducted by micro-computed tomography 
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(micro-CT) imaging using a Locus Ultra micro-CT scanner (GE 
Healthcare) (23). Following a 4 h fast, mice were anesthetized 
with 1.5% isoflurane in O2. The scan protocol consisted of an 
X-ray tube voltage of 80 kVP and a current of 55.0 mA. A calibrat-
ing phantom, comprising air and water, was scanned concurrently 
as a calibrator that enabled the conversion of the reconstructed 
image values into CT numbers [Hounsfield units (HU)]. In a scan 
time of 16 s, 1,000 views were acquired in one continuous rotation. 
Images were reconstructed to an isotropic voxel size of 150 m3. 
The analysis was conducted using MicroView software version 
2.2 (GE Healthcare). Total adipose tissue volume was calculated 
by selecting all voxels with values within a window of 225 to 60 
HU and then divided into subcutaneous and visceral depots. 
Subcutaneous and visceral adipose tissue depots were differenti-
ated using the muscular abdominal wall, which is readily identifi-
able because of its higher density (24). The subcutaneous and 
visceral adipose depots were outlined manually and the volume of 
each region was calculated by MicroView as the number of voxels 
falling within the threshold window multiplied by voxel volume 
(150 m3).
Glucose and insulin tolerance tests
A glucose tolerance test was performed following a 6 h fast by 
intraperitoneal injection with 15% glucose in 0.9% NaCl (1 g/kg 
body weight) (15). Blood samples for glucose measurements 
(Bayer contour blood glucose monitoring system; Bayer Health-
care) were taken up to 120 min postinjection. An insulin toler-
ance test was conducted following a 5 h fast by intraperitoneal 
injection with insulin (0.6 IU/kg body weight; Novolin GE To-
ronto, Novo Nordisk, Cooksville, ON, Canada) (15). Blood sam-
ples for glucose measurements were obtained up to 60 min 
postinjection. Glucose and insulin tolerance were calculated as a 
percent change in blood glucose from baseline.
Tissue lipids
Lipids from liver, quadriceps, gastrocnemii, and solei, and full-
length aortae dissected free of fat and connective tissue were ex-
tracted using the method of Folch from samples stored at 80°C, 
as described previously (14, 25). The [cholesteryl-1,2-3H(N)]cho-
lesteryl oleate (PerkinElmer, Guelph, Canada; #NET746L) was 
added to assess recovery. A combined 200 g/ml triolein and 200 
g/ml cholesterol standard was prepared in isopropanol and ali-
quoted for standard curves (0–20 g). Samples and standards 
were dried under N2 and a 1% Triton X-100 solution in chloro-
form added and left at room temperature for 1 h to solubilize. 
Samples and standards were dried under N2, followed by the addi-
tion of deionized water and incubation at 37°C for 15 min. Sam-
ples were analyzed using enzymatic reagents for triglyceride (TG) 
(Roche Diagnostics, Laval, Canada; TGs/glycerol blanked, #11877771 
216), total cholesterol (TC) (WAKO Diagnostics, Richmond, VA; 
cholesterol E (CHOD-DAOS method), #439-17501), and free 
cholesterol (WAKO Diagnostics; free cholesterol (COD-DAOS) 
method, #435-35801). Cholesteryl ester (CE) was determined as 
the difference between TC and free cholesterol.
Plasma measurements
Plasma TG and TC were measured on a Cobas Mira S autoana-
lyzer (Roche Diagnostics) using calibrators and controls from 
Roche Diagnostics (15). Enzymatic reagents for TG (Roche Diag-
nostics; TGs/glycerol blanked, #11877771 216) and cholesterol 
(Roche Diagnostics; Cholesterol CHOD-PAP, #11491458-216) were 
used. Fresh-EDTA plasma (50 l) was separated by fast-protein LC 
(FPLC) using an AKTA purifier and a Superose 6 column (14). A 
constant flow rate of 0.4 ml/min was used to collect 500 l frac-
tions. An aliquot of each fraction was used to measure cholesterol 
and TGs enzymatically in both samples and standards on a mi-
crotiter plate with added enzymatic reagents [TG: Roche Diagnos-
tics, TGs/glycerol blanked, #11877771 216 and TC: WAKO 
Diagnostics, Cholesterol E: (CHOD-DAOS method), #439-17501]. 
Blood glucose was measured in whole blood using the Bayer con-
tour blood glucose monitoring system (Bayer Healthcare, Etobicoke, 
Canada) (15). Plasma insulin (ALPCO Diagnostics, Salem, NH; 
mouse ultrasensitive ELISA #80-INSMSU-E01) was determined in 
EDTA-plasma samples, stored at 80°C, by a mouse-specific ELISA. 
Homeostasis model assessment of insulin resistance (HOMA-IR) 
was calculated using the following formula, as previously described 
for mice: HOMA-IR = 26 × fasting insulin level (ng/ml) × fasting 
glucose level (mg/dl)/405 (26).
Liver beta oxidation
For hepatic fatty acid oxidation, fresh liver (250 mg) was ho-
mogenized in 0.1 M phosphate buffer (pH 7.2) containing 0.25 M 
sucrose, 1 mM EDTA, 1 mM dithiothreitol, and 10 l/ml of pro-
tease inhibitor (Sigma-Aldrich; #P8340). Homogenates were cen-
trifuged at 1,000 g at 4°C for 10 min. Twenty microliters of 
supernatant were incubated for 30 min at 37°C with constant 
shaking in 0.1 M phosphate buffer (pH 7.2) containing 150 mM 
KCl, 10 mM HEPES, 5 mM Tris malonate, 10 mM MgCl2, 1 mM 
carnitine, 5 mM ATP, and 2 Ci of [9,10-3H(N)]palmitic acid 
(PerkinElmer; #NET043001MC) per 50 M unlabeled palmitic 
acid complexed with 0.15% fatty acid-free BSA. Reactions were 
stopped with 200 l of 0.6 N perchloric acid and unreacted fatty 
acids extracted with hexanes. The 3H2O in the aqueous phase was 
measured by liquid scintillation counting (15, 27).
Gene expression
RNA was isolated from aliquots of liver, eWAT, iWAT, BAT, 
and whole aortae using Trizol reagent (Life Technologies, Missis-
sauga, ON, Canada). Reverse transcription of 1 g total RNA was 
performed using a high-capacity reverse transcription kit (Applied 
Biosystems; ABI) to yield cDNA. Specific mRNA abundances 
were measured by quantitative real-time PCR on an ABI ViiA 7 
sequence detection system according to the manufacturer’s in-
structions. In the eWAT, iWAT, and BAT, mRNA quantitation 
for Tnfa, Ccl2, Ccl3, Emr1, Ucp1, Cidea, Pdk4, Ppara, Lipe, and 
Pnpla2 was determined. In liver, mRNA quantitation for Cpt1a, 
Pgc1a, Srepf1c, Ppara, Acox1, Ccl2, Ccl3, and Tnfa was determined. 
In the aorta, mRNA quantitation for Ccl3, Il1b, Ccl2, Tnfa, Emr1, 
Ccr7, Abca1, and Abcg1 was determined. Samples (10 ng) of cDNA 
were assayed in triplicate in 10 l reactions using a standard 
curve quantitative real-time PCR protocol to calculate specific 
mRNA concentrations. Expression levels for each gene were 
normalized to Gapdh expression in each tissue. With the excep-
tion of Srebf1c, all primer and probe sets used were purchased as 
TaqMan assays (ABI). The probe and primer sequences for 
Srebf1c were designed from the known murine Srebf1 locus to 
determine splice junctions. The intervening intronic sequence 
was removed and primers and a probe were designed from the 
resultant Srebp1c exon1c-exon2 sequence using Primer Express 
2.0 software (ABI). Primers were obtained from Sigma-Genosys 
and the probes labeled 5′ with 6-carboxyfluorescein (FAM) and 
3′ with the quencher, MGB®, were from ABI (TaqMan assay 
for mouse Srebf1c: forward primer, CAGGCCCGGGAAGTCACT; 
reverse primer, GACCACGGAGCCATGGATT; probe, FAM- 
ATTTGAAGACATGCTCCA-MGB®).
Tissue histology and immunohistochemistry
Histological and morphometric analyses were performed as de-
scribed previously (14, 17). eWAT was fixed in 4% paraformalde-
hyde for 24 h, processed, embedded in paraffin, sectioned on a 
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Microm HM335E microtome (Thermo Fisher Scientific), and 
stained with H&E. Frozen serial sections (70–100 per heart, 10 m) 
of the aortic sinus from hearts frozen in OCT, initiating ante-
rior to the origin of the aortic valves, were prepared using a 
Leica CM 3050S cryostat. For quantitation of lesion area in the 
aortic sinus, sections were stained with oil red-O. Immunohisto-
chemistry staining for macrophages by CD68 (Bio-Rad, Missis-
sauga, Canada; MCA 1957), smooth muscle -actin (Abcam, 
Toronto, Canada; polyclonal rabbit anti-smooth muscle -actin, 
ab5694), and activated caspase-3 (Abcam; rabbit anti-active 
caspase-3, ab4051) was performed as described previously (28). 
Slides were fixed in acetone and blocked in 2% BSA (Sigma-
Aldrich). After incubation with primary antibody, a goat bioti-
nylated secondary antibody was used (Vector Laboratories, 
Burlington, ON, Canada). Slides were then incubated in peroxi-
dase blocking reagent, followed by incubation with the ABC re-
agent (ABC Elite Standard kit; Vector Laboratories). Slides were 
exposed to the DAB substrate (peroxidase substrate kit; Vector 
Laboratories) followed by counterstain in hematoxylin (Sigma-
Aldrich). Photomicrographs were obtained using an Olympus 
BX50 microscope and a QImaging Retiga EXi FAST camera. 
Collagen fibrils were assessed using circular polarizing micros-
copy as described previously (28). Aortic sinus sections were 
stained with picrosirius red (Polysciences, Warrington, PA) and 
visualized using an Olympus BX51 microscope (Olympus Can-
ada, Richmond Hill, Canada) equipped with circular polarizer/
interference filters, a liquid crystal compensator, a charge-coupled 
device video camera, and Abrio image-processing software (Abrio 
LC-Polscope; Cambridge Research and Instrumentation, Inc., 
Hopkinton, MA).
Morphometric analysis of lesion area, necrotic core area, CD68, 
smooth muscle -actin, and collagen in lesions from mice from 
each group was performed on serial sections. The relative area 
of the atherosclerotic plaque positive for CD68, smooth muscle 
-actin, or collagen was determined as the area of positive staining 
divided by the area of the respective plaque. Quantitation was de-
termined using ImageJ 1.50 software (National Institutes of 
Health) for CD68, smooth muscle -actin, and collagen, or Axio-
Vision software for lesion area and necrotic core size. To deter-
mine the relative activation of caspase-3, the number of cell nuclei 
immunostained for activated caspase-3 was expressed as a per-
centage of the total lesion area. To ensure that a standard region 
was measured in each mouse, lesion analyses began at the origin 
of the aortic valves. All quantitations were performed indepen-
dently by three people.
Flow cytometry
Blood and bone marrow cell analyses were performed in a sep-
arate experiment in Ldlr/ mice (n = 8 per group) using the 
same induction and intervention protocol described above.
Blood leukocytes. Monocytes and neutrophils were identified 
from whole blood. At euthanization, blood was collected by car-
diac puncture into EDTA-lined tubes and immediately placed on 
ice. For each mouse sample, 100 l of blood was used. UltraComp 
eBeads (Affymetrix eBiosciences, Cedarlane, Burlington, ON, 
Canada; #01-2222) were used as a single positive control, except 
for the single positive control for the Vital Dye, where ArC™ 
amine reactive compensation bead kit was used (A10346; Life 
Technologies, Burlington, ON, Canada). Fluorescence minus 
one controls were performed on combined blood samples from 
all mice, 100 l each. Viability was assessed using LIVE/DEAD® 
fixable dead cell near-IR stain kit (L11019; Invitrogen, Life Tech-
nologies) (supplemental Table S1) in all samples after incuba-
tion for 25 min in the dark at room temperature. Cells were 
stained with a cocktail of antibodies against CD45-eFluor®450 
(Affymetrix eBiosciences, Cedarlane), Ly6-C/G-PerCP-Cy™5.5 
(BD Biosciences, Cedarlane, Burlington, ON, Canada), and 
CD115-APC (Affymetrix eBiosciences) on ice for 20 min in the 
dark (supplemental Table S1), similar to previous studies (29). 
Red blood cells were lysed in 1× PharmLyse (BD Biosciences) for 
13 min at room temperature. The stained white blood cells were 
centrifuged, washed, and resuspended in flow-buffer (HBSS + 
0.1% BSA, w/v). Cells were fixed by the addition of 4% parafor-
maldehyde. Monocytes were identified as CD45hi CD115hi and 
further identified into Ly6-Chi and Ly6-Clo; neutrophils were iden-
tified as CD45hi CD115lo Ly6-C/Ghi (Gr-1), similar to previous 
studies (supplemental Fig. S1A) (29).
Hematopoietic stem cells. Hematopoietic stem and progenitor 
cells from the bone marrow were analyzed by flow cytometry. 
Bone marrow was harvested from femurs and tibias by flushing 
with HBSS + 0.1% BSA w/v through a 70 m cell strainer. The cell 
suspension was centrifuged for 5 min at 500 g at 6°C, superna-
tant aspirated, and the cells resuspended in 1× PharmLyse (BD 
Biosciences) for 5 min. Red blood cell lysis was stopped by the 
addition of excess HBSS + 0.1% BSA. Cells were once again centri-
fuged at 500 g for 5 min at 6°C and the supernatant aspirated. 
Cells were resuspended in 1 ml HBSS + 0.1% BSA and blocked 
with normal goat serum. Cells were once again centrifuged at 500 
g for 5 min at 6°C and the supernatant aspirated. Bone marrow 
was resuspended in 4 ml of HBSS + 0.1% BSA. For each mouse 
bone marrow sample, 150 l of suspension were used. UltraComp 
eBeads (Affymetrix eBiosciences; #01-2222) were used as a single 
positive control, except for the single positive control for the Vital 
Dye, where the ArC™ amine reactive compensation bead kit was 
used (A10346; Life Technologies). Fluorescence minus one con-
trols were done on combined samples from all mice, 150 l each. 
Viability was assessed using LIVE/DEAD® fixable dead cell near-
IR stain kit (L11019; Invitrogen, Life Technologies) (supplemen-
tal Table S1) in all samples after incubation for 25 min in the dark 
at room temperature. Cells were stained with a cocktail of anti-
bodies against FITC mouse hematopoietic lineage cocktail 
[CD3 (17A2), CD45R (B220)(RA3-6B2), CD11b (M1/70), TER-
119, Ly-G6 (Gr-1) (RB6-8C5)] (Affymetrix eBiosciences), Brilliant 
Violet 421™ anti-mouse CD117 (c-Kit) (Biolegend, Cedarlane), 
Brilliant Violet 605™ anti-mouse Ly-6A/E (Sca-1) (Biolegend), Alexa 
Fluor®700 anti-mouse CD16/32 (Affymetrix eBiosciences), and 
PE anti-mouse CD34 (Biolegend) on ice for 20 min in the dark 
(supplemental Table S1) similar to previous studies (29). The 
stained white blood cells were centrifuged, washed, and resus-
pended in flow-buffer (HBSS + 0.1% BSA, w/v). Cells were fixed 
by the addition of 4% paraformaldehyde. Hematopoietic stem 
and progenitor cells were identified as Lin, Sca-1+, and ckit+, 
while the hematopoietic progenitor subsets were separated using 
antibodies to CD16/32 (FcRII/III) and CD34. Common myeloid 
progenitors were identified as lin, Sca-1, ckit+, CD34hi, and 
FcRII/IIIlo; granulocyte macrophage progenitors were identified 
as lin, Sca-1, ckit+, CD34hi, and FcRII/IIIhi; megakaryocyte and 
erythrocyte progenitors were identified as lin, Sca-1, ckit+, CD34lo, 
and FcRII/IIIlo (supplemental Fig. S1B).
Flow cytometry was performed using an LSRII (for analysis) 
running FACS DiVa software. All flow cytometry data were ana-
lyzed using FlowJo software (Tree Star Inc.)
Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were 
performed using Sigma Plot version 14.0. A one-way ANOVA with 
post hoc Tukey’s test was used to test for differences between 
groups, except in the case of body weight and adiposity measured 
over time where a two-way repeated measures ANOVA with post 
hoc Tukey’s test was used. Significance thresholds were P < 0.05. 
Significance differences are indicated by different lowercase 
letters. A Student’s t-test was used to test for differences in 
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ANCOVA-adjusted energy expenditure. Significant differences 
(P < 0.05) are indicated by an asterisk.
RESULTS
Flavonoid intervention promotes weight loss and 
attenuates adiposity
Previously, we determined that addition of either narin-
genin or nobiletin to a HFHC diet prevented the develop-
ment of many of the disorders of the metabolic syndrome 
and prevented atherosclerosis (15–17). To determine the 
therapeutic utility of these flavonoids, we sought to assess 
their efficacy in an intervention model where these disor-
ders were preestablished. Mice were initially fed a HFHC 
diet over 12 weeks to induce obesity, metabolic syndrome, 
and intermediate atherosclerotic lesions, and establish a 
disease baseline to which the efficacy of intervention was 
evaluated (Fig. 1A). Subsequently, mice were divided 
among four treatment groups for the subsequent 12 weeks: 
one group remained on the HFHC diet; a second group 
received intervention with regular mouse chow; a third 
group received intervention with the HFHC diet supple-
mented with 3% naringenin; and the fourth group re-
ceived intervention with the HFHC diet supplemented 
with 0.3% nobiletin (Fig. 1A).
All mice gained weight over the initial 12 week induction 
phase. Subsequently, mice that remained on the HFHC 
diet increased their body weight a further 20% (Fig. 1B). 
Mice that received intervention with naringenin or nobile-
tin, while also remaining on the same HFHC diet, lost 
13% of the body weight gained during the induction 
phase, a loss similar to that observed in the chow diet inter-
vention group (Fig. 1B). Chow intervention suppressed 
food intake during the first week, due to the abrupt change 
in food texture, but was rapidly resolved (Fig. 1C). Inter-
vention with the addition of naringenin or nobiletin to the 
HFHC diet did not significantly reduce caloric intake 
throughout the 12 weeks of intervention, suggesting that 
there was no flavonoid effect on satiety or feeding behavior 
(Fig. 1C).
Epididymal fat depots were increased during induc-
tion with the HFHC diet (Fig. 1D). Compared with base-
line, intervention with naringenin or nobiletin reduced 
epididymal fat by 29% and 44%, respectively, similar to 
the fat loss in chow-intervened mice (Fig. 1D). By con-
trast, in mice that remained on the HFHC diet alone, epi-
didymal fat mass increased by 28%. The same trends 
were observed for inguinal adipose tissue (supplemental 
Fig. S2A). In a separate study, we confirmed the interven-
tion-induced adipose tissue reductions with the flavo-
noids by micro-CT (Fig. 1E, supplemental Fig. S2B). 
Micro-CT showed that visceral fat volume was reduced 
38–53% and subcutaneous fat volume was reduced 23–
43% by flavonoid intervention (Fig. 1E, supplemental 
Fig. S2B). Importantly, lean tissue volume did not signifi-
cantly change during the 12 weeks of intervention (Fig. 1F), 
indicating that the intervention-induced weight loss was 
driven by a reduction in adiposity.
Flavonoid intervention reduced adipose tissue 
inflammation
Previous prevention studies demonstrated that narin-
genin attenuated adipocyte hypertrophy and adipose tissue 
inflammation in HFHC-fed Ldlr/ mice (14). In the pres-
ent study, compared with mice that remained on the HFHC 
diet, intervention by either naringenin, nobiletin, or chow 
induced a shift in epididymal adipocyte area toward smaller 
adipocytes by 19, 23, and 30%, respectively (Fig. 1G). Simi-
larly, flavonoid-treated mice had smaller adipocytes in in-
guinal adipose tissue (supplemental Fig. S2A). We next 
measured the mRNA expression of inflammatory genes in 
eWAT, iWAT, and BAT. Consistently, intervention with 
naringenin or nobiletin reduced mean mRNA expressions 
of Tnfa, Ccl2, and Ccl3, similar to reductions observed with 
chow intervention. Although not statistically significant, 
these reductions suggest a shift to resolution of obesity- 
associated adipose tissue inflammation (supplemental Fig. 
S3A). To try to understand whether the reduction in 
adiposity was due to browning or enhanced lipolysis, 
the mRNA expression of known markers of adipose tissue 
browning and lipolysis was measured. Treatment with nobi-
letin, but not naringenin or chow, increased the mean 
Ucp1 mRNA expression in epididymal and inguinal adi-
pose tissue (not significant). No intervention altered Ucp1 
expression in BAT (supplemental Fig. S3B). Neither in-
tervention with naringenin, nobiletin, nor chow affected 
mRNA expression of other browning markers, Cidea, Pdk4, 
and Ppara, or the lipolysis-associated genes, Lipe and Pnpla2, 
in iWAT, eWAT, or BAT (supplemental Fig. S3B, C). This 
suggests that the reduction in adiposity with each interven-
tion was not likely mediated directly through browning or 
enhanced lipolysis within white adipose tissue. Histological 
assessment of BAT revealed that naringenin or nobiletin 
intervention reduced tissue lipid accumulation similar to 
intervention with chow (supplemental Fig. S3D).
Flavonoid intervention increases energy expenditure
Previous prevention studies have shown that the addition 
of either flavonoid to the HFHC diet increased weight- 
normalized energy expenditure in mice (14, 16). Therefore, 
we assessed whether flavonoid intervention would also cor-
rect obesity-associated suppressed energy expenditure. Fol-
lowing HFHC diet induction, intervention with either 
naringenin or nobiletin increased ANCOVA-adjusted energy 
expenditure in both the light and dark cycles, com-
pared with mice that continued on the HFHC diet alone, 
suggesting a compound-mediated mechanism (Fig. 2A). 
The RER, which is indicative of metabolic fuel source, was 
also altered by flavonoid intervention. Mice that continued 
on the HFHC diet alone had a mean RER in the light cycle 
of 0.82, which decreased to 0.75 in the dark cycle, indica-
tive of fat as the primary metabolic fuel source over 24 h 
(Fig. 2B). Interestingly, intervention with either flavonoid 
to the HFHC diet maintained an RER 0.8 during the 
dark cycle, when mice consume the majority of their daily 
caloric intake (30). This indicates a shift to a combination 
of carbohydrate and fat utilization in the flavonoid-treated 
mice (Fig. 2B). Intervention with the chow diet increased 
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RER to 0.9 over 24 h, indicating enhanced oxidation of 
carbohydrates. In mice intervened with either flavonoid, 
food consumption increased by 2.5 kcal or 0.5 g per day, 
selectively in the dark cycle (Fig. 2C) and without changes 
in ambulatory activity (Fig. 2D). This small increase in food 
intake was not likely detectable when measured every 3 days 
in standard housing (Fig. 1C). Altogether, this suggests 
that flavonoid intervention enhanced energy expenditure 
and might induce a mild starvation response promoting 
greater food intake.
Flavonoid intervention normalizes insulin sensitivity
The ability of intervention with naringenin or nobiletin 
to reverse established insulin resistance was assessed. After 
induction with the HFHC diet, Ldlr/ mice developed 
elevated fasting plasma insulin and mild hyperglycemia 
(Fig. 3A, B). Intervention with chow reversed hyperinsu-
linemia (61%) and modestly improved hyperglycemia 
(15%). The addition of either naringenin or nobiletin to 
the HFHC diet reversed hyperinsulinemia at week 24 by 
50% and 54%, respectively, suggesting enhanced insulin 
sensitivity despite the concomitant HFHC diet (Fig. 3A). 
These significant reductions in fasting insulin levels were 
accompanied by decreases in fasting glucose by interven-
tion with naringenin (13%, trend) and nobiletin (35%) 
(Fig. 3B). Temporally, improvements in fasting glucose were 
observed at 6 weeks of flavonoid intervention and were 
maintained up to 12 weeks (Fig. 3C). HOMA-IR calculations 
showed that intervention with either flavonoid restored 
HOMA-IR to similar levels observed in chow-intervened 
mice (Fig. 3D). To determine whether normalized fast-
ing insulin levels resulted in improved insulin or glucose 
tolerance, both tolerance tests were performed at baseline 
and after 12 weeks of intervention (Fig. 3E–J). At baseline, 
all groups had similar insulin tolerance or clearance of glu-
cose shown as change in blood glucose concentration over 
time (Fig. 3E) and percent change in glucose over time 
(Fig. 3F). Following intervention, the lower fasting glucose 
levels in flavonoid-treated mice were accompanied by lower 
insulin tolerance test area under the plasma glucose curve 
[area under the curve (AUC)] (Fig. 3G), but there was no 
change in the efficiency of glucose clearance over time 
(Fig. 3H), suggesting that improved insulin tolerance did 
not enhance glucose clearance. Intervention with chow did 
not affect insulin tolerance (Fig. 3H). Similar glucose toler-
ance was observed in all groups following 12 weeks of in-
duction (Fig. 3I). Intervention with the addition of either 
naringenin or nobiletin to the HFHC diet or with chow 
improved glucose tolerance compared with mice that re-
mained on the HFHC diet alone (Fig. 3J). To understand 
peripheral insulin sensitivity further, we assessed muscle 
TG accumulation in quadriceps and gastrocnemii, which is 
known to impair insulin signaling (31) (Fig. 3K, L). The ac-
cumulation of TG in both the quadriceps and gastrocnemius 
Fig. 1. Intervention with citrus flavonoids promotes 
weight loss and decreases adiposity. Ldlr/ mice were 
fed a HFHC diet for 12 weeks. Subsequently, the same 
mice were treated with flavonoids added to the HFHC 
diet for an additional 12 weeks. A: Structure of narin-
genin (Nar) and nobiletin (Nob), and study design. B: 
Body weight measured weekly following intervention 
after induction (n = 6–10 per group). C: Caloric intake 
measured weekly during intervention (n = 6–10 per 
group). D: Adiposity assessed as epididymal fat pad 
weight/total body weight (n = 6–10 per group). E; Vis-
ceral and subcutaneous fat volume assessed by micro-
CT (n = 6 per group). F: Lean tissue volume assessed 
by micro-CT (n = 6 per group). G: Frequency distribu-
tion of adipocyte area in mice at the end of interven-
tion (n = 6 per group). Inset shows mean adipocyte 
area. Representative images of eWAT stained with 
H&E. Scale bar is 100 m. Data represent the mean ± 
SEM. Different letters are statistically different by 
two-way ANOVA with post hoc Tukey test (B, C, E, F) 
and one-way ANOVA with post hoc Tukey test (D, G) 
(P < 0.05). N.S., not significant.
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muscles was elevated at baseline and increased further by 
continuation on the HFHC diet (Fig. 3K, L). In quadri-
ceps, intervention with naringenin, nobiletin, or chow 
reversed TG accumulation from baseline (Fig. 3K). In gas-
trocnemii, intervention with either flavonoid or chow de-
creased the mean TG levels from baseline (trend), but were 
significantly lower compared with TG levels in HFHC-fed 
mice at 24 weeks (Fig. 3L).
Flavonoid intervention improves fatty liver
Ldlr/ mice fed the HFHC induction diet accumulated 
both hepatic TGs and cholesterol (Fig. 4A–C). Compared 
with baseline, liver TG levels were reversed with interven-
tion by either naringenin (28%), nobiletin (40%), or 
chow (70%) (Fig. 4A). Compared with the HFHC diet at 
24 weeks, intervention with either flavonoid or chow re-
duced liver TG by 58–82%. Compared with both baseline 
and HFHC at 24 weeks, liver CE and free cholesterol were 
lower with intervention by either naringenin (70%, 
40%), nobiletin (60%, 33%), or chow (90%, 53%), 
respectively (Fig. 4B, C). In prevention studies, we reported 
that a primary mechanism for flavonoid-induced reduc-
tions in liver lipids and associated metabolic abnormalities 
was enhanced Pgc1a- and Cpt1a-mediated fatty acid oxida-
tion and attenuated Srebp1c-induced fatty acid synthesis 
(15, 16). In the present study, intervention with the addi-
tion of either naringenin or nobiletin to the HFHC diet 
reversed the HFHC diet-induced suppression of hepatic 
fatty acid oxidation, increasing it by 2-fold compared with 
baseline and by 1.4-fold compared with HFHC-fed mice at 
24 weeks (Fig. 4D, E). This was accompanied by enhanced 
liver mRNA expression of Cpt1a and Pgc1a. Improvements 
in hepatic lipids with flavonoid or chow intervention were 
associated with a reduction in Srebf1c mRNA expression 
with naringenin (trend), nobiletin, and chow (Fig. 4E), 
suggesting reduced hepatic de novo lipogenesis. Liver 
weight was reduced with flavonoid treatment and there was 
no effect on hepatic Acox1 and Ppara mRNA expression, 
indicating that the flavonoid effects were independent of 
peroxisome proliferation or activation of PPAR, consis-
tent with our previous prevention studies (Fig. 4F; supple-
mental Fig. S4A, B) (16). Hepatic inflammation is also 
exacerbated by high-fat feeding (14). Intervention with ei-
ther flavonoid in addition to HFHC completely normalized 
the mRNA expression of hepatic Ccl2, Ccl3, Tnfa, and Il1b, 
consistent with decreases in hepatic lipids and improve-
ments in hepatic function (supplemental Fig. S4C–F).
Flavonoid intervention improves hyperlipidemia
Upon HFHC diet feeding, Ldlr/ mice developed hy-
percholesterolemia and hypertriglyceridemia (Fig. 5A–G). 
Intervention with naringenin or nobiletin supplementation 
to the HFHC diet for 12 weeks reduced plasma cholesterol 
(>50%) and TGs (>50%) (Fig. 5A, B). Flavonoid-mediated 
plasma lipid lowering was confined to VLDL- and LDL- 
cholesterol with no change in HDL-cholesterol levels (Fig. 
5C–H). Greater VLDL- and LDL-cholesterol reductions 
were observed with chow intervention (Fig. 5F, G).
Flavonoid intervention does not elicit atherosclerotic 
lesion contraction
Due to the significant improvement in atherosclerotic 
risk factors, we sought to determine the impact of flavo-
noid intervention on atherosclerosis regression. Aortic sinus 
lesions were assessed after HFHC induction (baseline) and 
Fig. 2. Intervention with citrus flavonoids increases energy ex-
penditure. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subse-
quently, the same mice were treated with flavonoids added to the 
HFHC diet for an additional 12 weeks. Between weeks 8 and 12 of 
intervention, mice were assessed in metabolic cages. A: ANCOVA-
adjusted energy expenditure (kilocalories per hour) over 24 h and 
mean ANCOVA-adjusted energy expenditure in both the dark and 
light periods (n = 6–8 per group). B: RER over 24 h and mean RER in 
both the dark and light periods (n = 6–8 per group). C: Accumulated 
food intake over 24 h and total food eaten during 24 h (n = 6–8 per 
group). D: Ambulatory activity over 24 h and mean ambulatory 
activity per hour (n = 6–8 per group). Data represent the mean ± 
SEM. Different letters are statistically different by ANOVA with post 
hoc Tukey test (P < 0.05). *Indicates statistically significant by Stu-
dent’s t-test (P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not 
significant.
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Fig. 3. Intervention with citrus flavonoids restores glucose homeostasis. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subsequently the 
same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. A: Fasting (6 h) plasma insulin levels (n = 17–20 
per group). B: Fasting (6 h) blood glucose (n = 10–32 per group). C: Fasting (6 h) blood glucose in the same mice at baseline and 6 weeks 
and 12 weeks of intervention (n = 11 per group). D: HOMA-IR (n = 7–12 per group). E, F: Insulin tolerance test (ITT) at baseline shown as 
blood glucose concentrations (n = 4–6 per group) (E) and percent change in glucose from time = 0 (n = 6–9 per group) (F). G, H; ITT at 
12 weeks intervention shown as blood glucose concentrations (n = 5–6 per group) (G) and percent change in glucose from time = 0 (n = 
22–24 per group) (H). I: Glucose tolerance test (GTT) at baseline (n = 6–9 per group). J: GTT at 12 weeks intervention (n = 10–11 per 
group). K, L: Muscle TG content in quadriceps (n = 8 per group) (K) and gastrocnemii and solei (n = 7–8 per group) (L). Data represent 
the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin; 
N.S., not significant.
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following flavonoid or chow intervention (Fig. 6A). While 
intervention with chow did not induce regression of aortic 
sinus lesions, their growth in size was significantly attenu-
ated. Intervention with either citrus flavonoid to the HFHC 
diet did not affect lesion size; the area of sinus lesions con-
tinued to increase at the same rate as in mice fed the HFHC 
diet alone for 24 weeks (Fig. 6A). Lipid measurements in 
whole aortae, dissected free from fat, revealed that the aor-
tae of HFHC-fed mice continued to accumulate free cho-
lesterol and CE (4-fold) compared with baseline (Fig. 
6B). The addition of either flavonoid at intervention 
slowed, but did not halt, the accumulation of aortic free or 
esterified cholesterol (Fig. 6B). Chow intervention pre-
vented further increases from baseline in aortic cholesterol 
content. The aortic mRNA expression of the inflamma-
tory genes, Ccl3, Tnfa, and Emr1, increased from baseline 
with continued HFHC, which was not offset by flavonoid 
intervention (Fig. 6C). Aortic mRNA of Il1b and Ccl2 were 
not different from baseline in mice continued on HFHC or 
with flavonoid intervention. Chow intervention tended to 
halt or reverse aortic mRNA expression of all inflammatory 
markers examined (Fig. 6C). Additionally, intervention 
with either flavonoid did not increase the expression of 
genes linked to regression and chow intervention actually 
decreased the mRNA expression of Ccr7, Abca1, and Abcg1 
(Fig. 6C).
Fig. 4. Intervention with citrus flavonoids increases hepatic fatty 
acid oxidation and reduces liver steatosis. Ldlr/ mice were fed a 
HFHC diet for 12 weeks. Subsequently, the same mice were treated 
with flavonoids added to the HFHC diet for an additional 12 weeks. 
A: Hepatic TGs (n = 7–8 per group). B: Hepatic CE (n = 7–8 per 
group). C: Hepatic free cholesterol (n = 7–8 per group). D: Ex vivo 
hepatic fatty acid oxidation (n = 7–10 per group). E: Hepatic gene 
expression (n = 12 per group). F: Liver weight (n = 22 per group). 
Data represent the mean ± SEM. Different letters are statistically 
different by ANOVA with post hoc Tukey test (P < 0.05). Nar, narin-
genin; Nob, nobiletin.
Fig. 5. Intervention with citrus flavonoids lowers plasma lipids from 
baseline. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subse-
quently, the same mice were treated with flavonoids added to the 
HFHC diet for an additional 12 weeks. Mice were fasted for 6 h prior 
to euthanization. Plasma was subjected to FPLC and lipids were mea-
sured in each fraction by enzymatic assay. A: Plasma TGs (n = 19–24 
per group). B: Plasma cholesterol (C) (n = 21–24 per group). C: 
Plasma TG FPLC tracing (n = 6–7 per group). D: Plasma VLDL TG 
AUC calculations (n = 6–7 per group). E: Plasma cholesterol FPLC 
tracing (n = 6–7 per group) F: Plasma VLDL cholesterol AUC calcula-
tions (n = 6–7 per group). G: Plasma LDL cholesterol AUC calcula-
tions (n = 6–7 per group). H: Plasma HDL cholesterol AUC 
calculations (n = 6–7 per group. Data represent the mean ± SEM. Dif-
ferent letters are statistically different by ANOVA with post hoc Tukey 
test (P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not significant.
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Flavonoid intervention reduces plaque macrophages
Although there was no change in the plaque size with 
flavonoid intervention, the decrease in aortic cholesterol 
suggested that lesion composition may have been favorably 
altered (Fig. 6A, B). After 12 weeks induction, plaques were 
comprised mainly of macrophages (66%) (Fig. 7A, H). 
Lesion macrophage content was reduced with interven-
tion by naringenin (47%), nobiletin (50%), and chow 
(69%) (Fig. 7A, H), consistent with the concept that de-
pletion of macrophages is characteristic of a regressing 
plaque (21). Although the percent of lesion area occupied 
by macrophages was also less in mice continuing on HFHC 
(23%), the decrease was greater with flavonoid or chow 
intervention (Fig. 7A, H). Compared with lesions at base-
line, continuation on the HFHC diet enlarged necrotic core 
area (from 6% to 14%), increased the percent of apoptotic 
cells (from 0.2% to 1.0%), reduced lesion smooth muscle 
cells (SMCs) (from 3.5% to 1.8%), and increased lesion 
collagen (from 20% to 35%) (Fig. 7B–F, Supplemental Fig. 
S5). Intervention with either naringenin, nobiletin, or 
chow halted the increase in necrotic core size, inhibited 
the increase in apoptosis, attenuated the decrease in SMCs, 
and maintained the increase in lesion collagen (Fig. 7B–F, 
supplemental Fig. S5). Collectively, these intervention-
induced changes in lesion composition are characteristic 
of more stable lesions (Fig. 7G).
Flavonoid intervention prevents enhanced monocytosis
Reduced plaque macrophage content is phenotypically 
associated with atherosclerosis regression (21, 32–34). 
Reduced monocyte recruitment from the circulation has 
been implicated as a mechanism contributing to regression 
(29). In this study, continuation of the HFHC diet in-
creased the number of circulating Ly6Chi monocytes (2-fold) 
(Fig. 8A), the monocyte subset known to be the precursor 
of lesion M1 and M2 macrophages (35). Intervention with 
chow or nobiletin completely prevented the increase in Ly-
6Chi monocytes, while with naringenin intervention, there 
was a trend to attenuation of the HFHC-induced elevation 
in Ly6Chi monocytes (Fig. 8A). There was no effect on cir-
culating Ly6Clo monocytes or total neutrophil levels with 
continuation of the HFHC diet or with any intervention 
(Fig. 8B, D). To investigate this trend further, bone mar-
row progenitor populations were measured (supplemental 
Fig. S6). Intervention with chow reduced bone marrow 
hematopoietic stem and progenitor cell populations, whereas 
Fig. 6. Intervention with citrus flavonoids does not attenuate lesion size but slows aortic cholesterol accumulation. Ldlr/ mice were fed 
a HFHC diet for 12 weeks. Subsequently, the same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. 
Aortae were dissected and the aortic sinus sectioned and analyzed histologically. A: Representative sections of the aortic sinus stained with oil 
red-O and hematoxylin and lesion area quantitation (n = 12–21 per group). Scale bar is 500 m. B: Total cholesterol (TC), cholesteryl ester 
CE, and free cholesterol (FC) in whole aortae (n = 6–8 per group). C: Gene expression in whole aortae (n = 6–8 per group). Data represent 
the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin; 
N.S., not significant.
1724 Journal of Lipid Research Volume 59, 2018
the modest reductions with flavonoid intervention were 
not significant (supplemental Fig. S6A, C). A similar trend 
persisted when looking at bone marrow myeloid progeni-
tor cells (supplemental Fig. S6B, C), common myeloid pro-
genitor cells (supplemental Fig. S6D, G), and granulocyte 
macrophage progenitor cells (supplemental Fig. S6E, G). 
There was no consistent effect of any treatment group on 
megakaryocyte and erythrocyte progenitor cells (supple-
mental Fig. S6F, G).
DISCUSSION
In the present study, we showed that intervention with 
the citrus-derived flavonoids, naringenin or nobiletin, when 
supplemented to a HFHC diet, reversed diet-induced 
obesity and insulin resistance, improved hyperlipidemia 
and hepatic steatosis, and favorably altered aortic sinus ath-
erosclerotic plaque composition. Flavonoid intervention 
enhanced energy expenditure, despite promoting a mod-
est increase in food consumption during the active time 
and while maintaining similar ambulatory activity. In the 
liver, fatty acid oxidation was increased, as were Cpt1a and 
Pgc1a expression, suggesting enhanced fat mobilization. In 
white adipose tissue, there were no consistent effects on 
browning genes in visceral or subcutaneous depots and no 
enhancement of browning genes in BAT, suggesting a non-
browning mechanism of enhanced energy expenditure 
and reduced adiposity. Although atherosclerotic lesion size 
was unaffected, the improvements in metabolic parameters 
with flavonoid intervention correlated with a reduction in 
circulating monocytes and reduced macrophage content 
in established atherosclerotic lesions, characteristics con-
sistent with atherosclerosis regression (22).
Changes in food consumption can result from the ef-
fects of dietary components or drugs on behavior, satiety, 
or energy balance, which in turn alter metabolic regula-
tion, including adipose tissue metabolism (30). Consistent 
with previously reported prevention studies, addition of 
flavonoids to the HFHC diet did not decrease caloric in-
take as measured in standard caging (13–16). Studies from 
other laboratories have reported reduced caloric intake in 
Fig. 7. Intervention with citrus flavonoids improves lesion morphology. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subsequently, the 
same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. Aortae were dissected and the aortic sinus sec-
tioned and analyzed histologically. A: Percent of lesion area occupied by CD68+ macrophages (n = 14–22 per group). B: Percent of lesion 
area occupied by the necrotic core (n = 14–17). C: Percent of lesion positive for activated capase-3 (n = 9–20 per group). D: Percent of lesion 
area occupied by SMCs (-actin) (n = 12–23 per group). E: Percent of lesion area occupied by collagen (picrosirius red) (n = 12–19 per 
group). F: Collagen organization measured as mean collagen fibril retardation (n = 12–19 per group). G: Lesion composition for each di-
etary group. H: Representative histological sections of the aortic sinus stained with CD68 (macrophages) and counterstained with hematoxy-
lin. Scale bar is 500 m. Data represent the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey test 
(P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not significant.
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high-fat-fed mice with naringenin intervention, leading to 
decreased body weight and adiposity (36), an effect likely 
attributed to a taste aversion to the compound when ad-
ministered in the food. In the present study, taste aversion 
was mitigated by starting intervention at a low flavonoid 
dose, which was slowly increased to the final dose over the 
first week of intervention. Thus, food intake did not drop 
precipitously, which would in itself cause weight loss. In 
metabolic cage studies, we unexpectedly identified a small 
(0.5 g/day) but significant increase in caloric consump-
tion during the dark cycle in both naringenin- and nobile-
tin-treated mice, at weeks 21–23, near the end of the 
intervention. Despite this small increase, intervention with 
both flavonoids induced weight loss, decreased adiposity, 
and improved metabolic indices, implying the molecular 
mechanism for the flavonoid effects was not related to sup-
pressed food intake (30). The reasons underlying the flavo-
noid-induced increase in caloric intake during the dark 
cycle is not well understood, but may be related to a mild 
starvation response resulting from increased energy expen-
diture. Pair-feeding experiments would help to confirm 
and further understand this observation.
Naringenin intervention has previously been studied in 
ovariectomized female C57BL/6J mice to assess its impact 
on postmenopausal metabolic dysfunction (36, 37). In 
chow-fed ovariectomized mice at a normal body weight, in-
tervention by the addition of naringenin to chow prevented 
weight gain while promoting modest weight loss, reduced 
adiposity, and improved glucose homeostasis, accompa-
nied by a reduction in caloric intake (36). When the same 
ovariectomized mice were fed a high-fat diet, intervention 
with the addition of naringenin to the high-fat diet pre-
vented further weight gain and adiposity, while increasing 
ambulatory activity, with no change in energy expenditure 
(37). In our male Ldlr/ mice fed a high-fat diet, interven-
tion with either flavonoid also decreased body weight and 
adiposity, but was due to an increase in ANCOVA-adjusted 
energy expenditure, with no change in ambulatory activity 
and despite a small increase in caloric intake. Ambulatory 
activity was lower in treated postmenopausal mice compared 
with our flavonoid-intervention in Ldlr/ mice, which 
might be attributed to postmenopausal sarcopenia. It is 
possible that the discrepancy in activity results could be 
due to differences in age and sex of the two models. The 
lack of effect of flavonoid intervention on activity is consis-
tent with our previous prevention studies in high-fat-fed 
Ldlr/ mice treated with both naringenin and nobiletin 
(15, 16). Experiments in age-matched female Ldlr/ mice 
would help to further understand this observation.
Hypercholesterolemia, hyperglycemia, obesity, and, more 
specifically, adipose tissue inflammation are all indepen-
dent risk factors for leukocytosis, which can contribute 
to accelerated atherosclerosis (32, 38, 39). In the present 
study, intervention with either naringenin or nobiletin re-
duced atherosclerotic lesion macrophage content, consistent 
with plaque regression. Reduced monocyte recruitment to 
atherosclerotic plaques is characteristic of atherosclerosis 
regression (21, 34). While trafficking kinetics to determine 
the contribution of monocyte recruitment to the reduced 
lesion macrophage content were not performed, leukocyte 
Fig. 8. Intervention with citrus flavonoids prevents further elevation in blood monocytes. Ldlr/ mice were fed a HFHC diet for 12 weeks. 
Subsequently the same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. Peripheral blood mononuclear 
cells (PBMCs) were isolated and stained for monocyte and neutrophil markers. A: Percent PBMCs that were Ly6Chi monocytes (n = 9–10 per 
group). B: Percent of PBMCs that were Ly6Clo monocytes (n = 9–10 per group). C: Percent of PBMCs that were both Ly6Chi and Ly6Clo 
monocytes. D: Percent of PBMCs that were neutrophils. E: Representative flow cytometric pseudocolor plots show monocytes and neutrophil 
populations from each dietary group. Data represent the mean ± SEM. Different letters are statistically different by ANOVA with post hoc 
Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not significant.
1726 Journal of Lipid Research Volume 59, 2018
levels in the circulation were quantitated. Intervention with 
naringenin or nobiletin prevented any further increase in 
circulating Ly6Chi monocytes, known to be the precursor 
of lesion macrophages (35). We also showed that interven-
tion with chow induced a more notable, but not significant, 
reduction from baseline in blood Ly6Chi monocytes com-
pared with flavonoid intervention, but this did not trans-
late into a reduction in circulating total monocytes. This 
chow-alone intervention effect is consistent with previous 
regression studies in high-fat-fed Ldlr/ mice (32), but not 
studies in high-fat-fed Ldlr/ mice in which the chow in-
tervention was coupled to hepatic Mttp deletion, which re-
sulted in more rapid regression and a large reduction in 
circulating monocytes (33). It is possible that interventions 
with dietary flavonoids plus HFHC or chow alone were not 
strong enough or long enough in duration to achieve 
larger significant reductions in circulating monocytes (32, 
33). In addition, neither flavonoid nor chow intervention 
completely corrected hypercholesterolemia, thereby re-
stricting a more robust reduction in myelopoiesis (38). 
Furthermore, we used Ldlr/ mice, which develop more 
modest monocytosis compared with Apoe/ mice in re-
sponse to a high-fat diet, which would make the effects of 
naringenin or nobiletin intervention more subtle, espe-
cially considering the incomplete correction of metabolic 
dysfunction (29).
The mechanism(s) through which either naringenin or 
nobiletin regulate energy expenditure, lipid metabolism, 
and insulin sensitivity are not completely understood. Pre-
vious in vitro studies demonstrated that both naringenin 
and nobiletin activate insulin signaling independent of the 
insulin receptor or insulin receptor substrate (16, 40). Ad-
ditionally, in high-fat-fed Ldlr/ mice, both naringenin 
and nobiletin upregulated Pcg1a- and Cpt1a-mediated he-
patic fatty acid oxidation, independent of peroxisomal pro-
liferation, and suppressed Srebp1c-mediated fatty acid 
synthesis (15, 16). The upstream mechanism(s) governing 
these effects have remained somewhat elusive. The hor-
mone-like fibroblast growth factor 21 elicits similar meta-
bolic improvements as naringenin when given exogenously 
to mice, but naringenin prevented metabolic dysfunction 
and obesity in high-fat-fed Fgf21/ mice to the same ex-
tent as in wild-type mice (13). In short-term treatment of 
Ob/Ob mice, naringenin supplementation to a low-fat diet 
reversed hyperlipidemia, attenuated body weight, and im-
proved hepatic steatosis and insulin sensitivity, indicating 
that the naringenin effect was independent of leptin defi-
ciency (13). This suggests that, unlike other natural com-
pounds, such as celastrol and withaferin A, naringenin does 
not work through enhancing leptin sensitivity (41, 42). 
Alternatively, celastrol has also been shown to prevent weight 
gain and improve metabolic dysfunction through activa-
tion of the heat shock factor 1-PGC1 axis in adipose tissue 
and muscle, but not liver (43), more similar to, but not 
identical to, the hepatic effects of naringenin or nobiletin.
Recent studies revealed that the addition of naringenin 
plus apigenin (a related flavonoid) to a high-fat diet pre-
vented the exacerbated rebound in body weight in mice, 
when rechallenged with a high-fat diet following a period 
of chow-induced weight loss (44). Celastrol or a leptin-sen-
sitizing antagonist did not mitigate weight rebound. Flavo-
noid treatment replaced the persistent high-fat diet-induced 
loss of microbiome-derived flavonoid availability, resulting 
in increased energy expenditure and upregulation of Ucp1 
expression in BAT (44). In prevention models, we have 
shown that naringenin modestly increases Ucp1 expression 
in iWAT (13); but in the present study, we saw no effect 
with either naringenin or nobiletin on iWAT or BAT Ucp1 
expression. Additionally, we reported no change with nobi-
letin treatment on nonshivering thermogenesis; however, 
experiments were not conducted at thermoneutrality (16). 
This suggests that flavonoid-mediated enhanced browning 
may not be the mechanism through which citrus flavo-
noids exert their anti-obesity effects. It is possible that the 
browning effect of flavonoids in the weight cycling mouse 
model was apigenin specific. Nobiletin, but not narin-
genin, has been shown to enhance the amplitude of cir-
cadian rhythms, specifically in obese mice (45). In our 
previous studies, we have not observed any differences in 
the effects of either naringenin or nobiletin treatment 
aside from potency. Nobiletin is 10 times more potent 
than naringenin, which is reflected in its lower effective 
dose (0.3% vs. 3% of diet) (15, 16). It is possible that nar-
ingenin may also enhance clock sensitivity and that differ-
ences in dosing and administration may be responsible for 
the discrepancy in results between naringenin and nobiletin 
(15, 45).
In the present study, we tested one protocol of induction 
and intervention times, 12 weeks induction with a HFHC 
diet followed by 12 weeks intervention with either citrus 
flavonoid supplemented to the HFHC diet. These time-
lines were chosen based on atherosclerosis regression 
models in the literature and are similar to other dietary 
flavonoid-intervention timelines (21, 36, 37). Twelve weeks 
of HFHC induction was sufficient time to induce moderate 
obesity, significant hyperlipidemia, moderate insulin resis-
tance, hepatic steatosis, and intermediate atherosclerosis. 
Twelve weeks intervention was sufficient to completely im-
prove obesity and insulin resistance, but moderate hyper-
lipidemia and hepatic steatosis persisted, resulting in 
improvements in lesion morphology, but no regression of 
plaque size. This raises the intriguing possibility that a lon-
ger duration of flavonoid intervention would result in 
greater resolution of these disorders. It would be of interest 
to test different intervention durations and potentially lon-
ger induction periods to test the limits of flavonoid inter-
vention on the resolution of diet-induced obesity, metabolic 
syndrome, and atherosclerosis.
A number of human studies using purified citrus flavo-
noids have demonstrated improvements in plasma lipids, 
glucose metabolism, and obesity [reviewed in (11)]. How-
ever, results were modest and inconsistencies between 
studies and considerable inter-patient variation were ob-
served. Bioavailability of flavonoids is low, especially in hu-
mans; metabolism of flavonoids differs between subjects 
and differences in the enteric microflora may be responsible 
for considerable inter-individual variability in absorption 
and pharmacokinetic parameters (11). Larger controlled 
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human studies are required to assess dose, bioavailability, 
efficacy, and safety for therapeutic development.
In summary, we have shown that intervention by the 
addition of either of the citrus flavonoids, naringenin or 
nobiletin, to a high-fat diet in obese mice reverses weight 
gain and adiposity similar to intervention with chow, with-
out reducing food intake. Mice treated with naringenin or 
nobiletin consume more calories, but expend more energy 
without increased ambulatory activity. Flavonoid-treated 
mice regain insulin sensitivity and reverse hyperinsulinemia 
completely. Plasma lipids are decreased and hepatic fatty 
acid oxidation is increased resulting in reduced hepatic lip-
ids. Collectively these improvements in atherogenic risk 
factors did not result in lesion contraction, but improved 
lesion morphology, most notably reduced lesion macro-
phage content, consistent with early stages of atherosclerosis 
regression. These studies highlight the potential therapeu-
tic utility of either naringenin or nobiletin, especially in the 
context of existing obesity and metabolic dysfunction.
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